Compound Detail
CHEMBL5095049
PACRITINIB CITRATE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Basic Information
| ChEMBL ID | CHEMBL5095049 |
| Name | PACRITINIB CITRATE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | BAHHBHSHSRTKNK-BJILWQEISA-N |
| Therapeutic | ✓ Yes |
| Parent Compound | CHEMBL2035187 |
| Active Moiety | CHEMBL2035187 |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
4
Known Names
2
Indications
5
Mechanisms
Molecular Properties
472.6
MW (Da)
4.47
ALogP
7
HBA
1
HBD
67.7
PSA (Ų)
0.67
QED
0
Ro5 Violations
4
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2022 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Tyrosine-protein kinase JAK2 inhibitor | INHIBITOR | Tyrosine-protein kinase JAK2 | ✓ | ✓ |
| Tyrosine-protein kinase receptor FLT3 inhibitor | INHIBITOR | Receptor-type tyrosine-protein kinase FLT3 | ✓ | ✓ |
| Tyrosine-protein kinase JAK2 inhibitor | INHIBITOR | Tyrosine-protein kinase JAK2 | ✓ | ✓ |
| Activin receptor type-1 inhibitor | INHIBITOR | Activin receptor type-1 | ✓ | ✓ |
| Interleukin-1 receptor-associated kinase 1 inhibitor | INHIBITOR | Interleukin-1 receptor-associated kinase 1 | ✓ | ✓ |
Indications
Polycythemia Vera Primary Myelofibrosis
Data from ChEMBL 36 via Core Engine